Navigation Links
NZymeCeuticals Announces the Introduction of New Bulk Ingredient 'Platinum Nattokinase' (PN20K) to Dietary Supplement Industry
Date:9/8/2008

indicates PN20K has the potential to significantly impact cardiovascular diseases because of its ability to change chemical and physical characteristics of blood, providing a "one-two punch." "We simply don't see these positive effects with typical pharmaceutical drugs," says Dr. Holsworth.

In Japan, the enzyme has an annual 15 billion yen market. Since its introduction to the U.S. market, bulk sales for the enzyme have experienced increased growth and demand. With different manufacturers of nattokinase from all over the world, the activity, stability and purity of the product varies significantly. NZymeCeuticals' bulk ingredients undergo third-party testing for quality assurance and quality control as well as to preserving the integrity of the new ingredient. Clinical research using PN20K as the therapeutic agent is well underway.

http://www.nzymeceuticals.com

###

Read the full story at http://www.prweb.com/releases/nattokinase/holsworth/prweb1294934.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services
2. Z Trim Holdings, Inc. Announces Private Placement Funding
3. The Risk Management and Patient Safety Institute Announces Agreement With Pioneering Health Care Simulation Organization, PSO One
4. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
5. Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBCs Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th
6. LIFE Foundation Announces 2008 realLIFEstories Award Recipients to Illustrate Benefits of Life and Disability Insurance
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2008
8. Custom Briefings Announces Launch of Endocrine Daily Briefing
9. Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss
10. Versus Technology Announces Third Quarter Results
11. Replidyne Announces Restructuring of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:NutraCea Announces Third Quarter 2008 Financial Results 2Health News:NutraCea Announces Third Quarter 2008 Financial Results 3Health News:NutraCea Announces Third Quarter 2008 Financial Results 4Health News:NutraCea Announces Third Quarter 2008 Financial Results 5Health News:NutraCea Announces Third Quarter 2008 Financial Results 6Health News:NutraCea Announces Third Quarter 2008 Financial Results 7Health News:NutraCea Announces Third Quarter 2008 Financial Results 8Health News:NutraCea Announces Third Quarter 2008 Financial Results 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 3Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 4Health News:More People Living Longer After Cancer Diagnosis 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Warner Chilcott Announces Secondary Equity Offering 6242 1Warner Chilcott Announces Secondary Equity Offering 6242 2Warner Chilcott Announces Secondary Equity Offering 6242 3Warner Chilcott Announces Secondary Equity Offering 6242 4Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 1Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 2Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 3Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 1Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 2Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 3Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 5Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 6Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 7
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3